6:33 PM
 | 
Dec 17, 2012
 |  BC Extra  |  Company News

NICE rebuffs Avastin for first-line ovarian cancer

The U.K.'s NICE issued draft guidance recommending against Avastin bevacizumab from Roche (SIX:ROG; OTCQX:RHHBY) for first-line treatment of advanced ovarian cancer in combination with paclitaxel and carboplatin. The committee questioned the overall survival (OS) benefit of Avastin plus paclitaxel and carboplatin because...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >